Avita Medical Secures $60M Credit Facility, Guides FY26 Revenue to $80-85M
AVITA Medical (ASX: AVH) has closed a five-year credit facility providing up to $60 million in committed capital from Perceptive Advisors, a healthcare-focused investment firm. The announcement, made ahead of the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on 14 January 2026, includes preliminary full-year 2025 financial results and 2026 revenue guidance. An initial $50 million has been funded, with an option to draw an additional $10 million through the end of first quarter 2027.
The new credit facility refinances existing debt and strengthens the capital structure whilst establishing trailing twelve-month (TTM) revenue covenants aligned with the company’s operating trajectory. Proceeds will be used to repay outstanding debt and support further growth of the acute wound care portfolio.
AVITA Medical Secures $60 Million Perceptive Advisors Facility to Fuel Growth
The credit facility represents a material refinancing event for the therapeutic acute wound care company, providing committed capital without immediate equity dilution. Perceptive Advisors, which manages assets focused on healthcare investments, brings sector-specific expertise alongside the capital commitment.
The facility’s structure includes an initial $50 million funding tranche, with management retaining the option to access an additional $10 million through Q1 2027. This staged approach provides financial flexibility whilst demonstrating institutional confidence in the company’s revenue trajectory and growth strategy.
Timing of the announcement, ahead of the J.P. Morgan Healthcare Conference presentation scheduled for 5:15 p.m. Pacific Time on 14 January 2026 (Thursday, 15 January 2026, at 12:15 p.m. Australian Eastern Daylight Time), positions the company to present its strengthened balance sheet to the institutional investor audience attending the annual event.
“We are pleased to partner with Perceptive Advisors, whose deep healthcare expertise and collaborative approach align well with our commitment to building a durable, growth-oriented business and our long-term vision,” said David O’Toole, Chief Financial Officer of AVITA Medical.
The partnership extends beyond capital provision. Perceptive Advisors’ track record in healthcare growth investing and their understanding of the acute wound care market provide strategic value as the company executes its commercialisation and clinical development plans.
When big ASX news breaks, our subscribers know first
What Does AVITA Medical’s New Debt Facility Mean for Investors?
The refinancing addresses several investor considerations simultaneously. It removes the overhang of existing debt obligations, resets revenue covenants to levels aligned with current operating performance, and preserves shareholder value by avoiding dilutive equity raises at what management believes represents an undervalued share price.
Revenue covenants function as performance benchmarks tied to the credit facility. They require the company to achieve specified revenue levels over trailing twelve-month periods. If revenue falls below these thresholds, it could trigger default provisions or require renegotiation.
The new facility establishes a TTM revenue covenant of $68.5 million for the first quarter ending 31 March 2026, and $73 million for full year 2026. Based on reported financial results for the three quarters ended 31 December 2025, the company will be required to achieve $15.4 million in revenue during Q1 2026 to meet the first covenant milestone.
| Period | Revenue Covenant | Context |
|---|---|---|
| Q1 2026 (ending 31 March 2026) | $68.5M (TTM) | Requires $15.4M Q1 revenue based on three quarters ended December 31, 2025 |
| Full Year 2026 | $73M (TTM) | Sits within 2026 guidance range of $80-85M |
| Guidance Midpoint | $82.5M | Provides $9.5M buffer above covenant |
Management characterised these covenants as “appropriate and manageable based on our operating performance and forward outlook.” The Q1 2026 requirement of $15.4 million represents approximately 12% below the Q4 2025 reported revenue of $17.6 million, building in a conservative buffer.
“AVITA Medical has established a differentiated position in acute wound care with a clear path to value creation through both commercial execution and clinical advancement,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “With multiple near-term catalysts, we believe the Company is well positioned to scale efficiently and progress toward sustainable profitability, and we are pleased to support the management team through this next phase of growth.”
The full year 2026 covenant of $73 million sits comfortably within the company’s 2026 guidance range of $80-85 million, providing an approximate $7-12 million cushion at the guidance boundaries.
Understanding Revenue Covenants in Credit Facilities
Revenue covenants are contractual requirements in debt agreements that specify minimum revenue levels a borrower must achieve over defined periods. For pre-profit or low-margin companies like AVITA Medical, revenue covenants provide lenders with measurable milestones to assess business trajectory and repayment capacity.
Unlike cash flow covenants (which focus on profitability metrics), revenue covenants track top-line growth. This structure aligns with AVITA Medical’s current stage, where the priority is expanding market adoption of its RECELL System and acute wound care portfolio before achieving sustained profitability.
The trailing twelve-month structure smooths quarterly volatility, measuring cumulative performance across four consecutive quarters rather than isolated period results. This approach reduces the risk that seasonal fluctuations or one-off events trigger covenant breaches.
For investors, covenant levels signal lender confidence in the business model. The reset to $68.5 million and $73 million thresholds suggests Perceptive Advisors conducted detailed due diligence on revenue forecasts and determined these levels were achievable whilst still protecting their capital position.
2025 Revenue Performance: Stabilisation Achieved at $71.6 Million
AVITA Medical reported preliminary unaudited full-year 2025 revenue of approximately $71.6 million, compared to $64.3 million in full year 2024. This represents approximately 11% year-on-year growth and falls within the company’s revised guidance range issued during 2025.
Fourth quarter 2025 revenue came in at approximately $17.6 million, compared to $18.4 million in Q4 2024.
The full-year result validates management’s revised expectations following mid-year guidance adjustments. Interim CEO Cary Vance framed 2025 as a foundation-building year focused on stabilising revenue, advancing clinical programmes, and improving financial flexibility.
“Over the past year, we have focused on strengthening the foundation of the business – stabilizing revenue, advancing our clinical pipeline, and improving financial flexibility,” said Vance. “With a strengthened balance sheet and key clinical and commercial milestones ahead, we enter 2026 positioned to shift from stabilization to execution-led growth and deliver more predictable, scaled performance.”
The stabilisation narrative sets the stage for 2026 guidance, which projects accelerated growth compared to the approximately 11% achieved in 2025.
How Is AVITA Medical Positioned for Growth in 2026?
Management provided preliminary 2026 revenue guidance in the range of approximately $80-85 million, representing growth of approximately 12-19% compared to 2025 revenue of $71.6 million. The midpoint of $82.5 million implies approximately 15% year-on-year expansion.
This guidance reflects management’s confidence in three growth drivers: improved commercial execution of the RECELL System, expected clinical data readouts from the Cohealyx-I and PermeaDerm-I studies, and the financial flexibility provided by the Perceptive Advisors facility.
The acceleration from approximately 11% growth in 2025 to a projected approximately 12-19% range in 2026 indicates management believes the stabilisation phase is complete. The company now shifts focus to scaling adoption across its acute wound care portfolio whilst maintaining the predictable performance trajectory emphasised in Vance’s commentary.
The revenue covenant structure aligns with this guidance. The full-year 2026 covenant of $73 million sits well below the low end of guidance ($80 million), providing a substantial buffer and suggesting Perceptive Advisors conducted conservative underwriting relative to management’s projections.
Clinical Pipeline as 2026 Value Driver
Two key clinical programmes achieved enrolment milestones in December 2025, positioning the company for data readouts later in 2026. The Cohealyx-I study reached full enrolment, whilst the PermeaDerm-I study surpassed 75% enrolment.
These trials assess the efficacy of AVITA Medical’s portfolio products beyond the flagship RECELL System:
- Cohealyx: A collagen-based dermal matrix for wound management
- PermeaDerm: A biosynthetic wound matrix
Expected data releases in 2026 could support expanded clinical applications, additional regulatory clearances, or improved reimbursement pathways. Positive trial results would diversify revenue streams beyond the thermal burn and trauma indications currently driving RECELL System sales.
The clinical progress demonstrates execution on the product pipeline strategy whilst the commercial team focuses on scaling existing approved products. This dual-track approach aims to sustain growth beyond 2026 as new indications or products enter the market.
Capital Deployment Strategy and Path to Profitability
The initial $50 million funding from the Perceptive Advisors facility will be allocated to two priorities:
- Repayment of existing debt obligations
- Investment in acute wound care portfolio growth initiatives
The optional $10 million tranche, available through Q1 2027, provides additional flexibility for opportunistic investments or working capital needs if 2026 revenue growth exceeds expectations or if clinical trial success creates accelerated commercialisation timelines.
Perceptive Advisors’ investment thesis centres on AVITA Medical’s path to sustainable profitability. Their portfolio management approach typically targets healthcare companies with proven technologies at inflection points where capital can accelerate scaling and operational efficiency.
“This financing represents an important step in strengthening AVITA Medical’s capital structure while preserving shareholder value, including a reset of our revenue covenants to levels we believe are appropriate and manageable based on our operating performance and forward outlook,” said David O’Toole, Chief Financial Officer.
The phrase “preserving shareholder value” references the alternative financing paths considered. Equity raises at current valuations would have diluted existing shareholders, whilst the debt structure maintains the existing ownership base whilst providing growth capital.
The next major ASX story will hit our subscribers first
What Are the Revenue Covenants in AVITA Medical’s Credit Agreement?
The credit agreement establishes trailing twelve-month revenue covenants at two checkpoints: Q1 2026 and full year 2026. These thresholds measure cumulative revenue across rolling four-quarter periods rather than individual quarter performance.
For Q1 2026 (period ending 31 March 2026), the TTM covenant is $68.5 million. This means the sum of revenue across the trailing twelve months must equal or exceed this threshold.
Based on the company’s reported financial results for the three quarters ended 31 December 2025, the company will be required to achieve $15.4 million in revenue in the first quarter 2026 to meet the covenant.
| Requirement | Amount | Notes |
|---|---|---|
| Q1 2026 TTM Revenue Covenant | $68.5M | Covenant threshold |
| Q1 2026 Required Revenue | $15.4M | Based on three quarters ended December 31, 2025 |
| Q4 2025 Revenue | $17.6M | Preliminary reported |
| Buffer | ~12% | Q1 2026 requirement vs Q4 2025 actual |
The Q1 2026 requirement of $15.4 million sits approximately 12% below Q4 2025 revenue of $17.6 million, indicating management and Perceptive Advisors built in a conservative buffer. This provides protection against normal quarterly variability whilst still ensuring the covenant drives performance accountability.
For full year 2026, the TTM covenant increases to $73 million. Assuming the company meets the Q1 2026 covenant and achieves the low end of 2026 guidance ($80 million), the full-year covenant would be exceeded by $7 million. At the guidance midpoint ($82.5 million), the buffer expands to $9.5 million.
The covenant structure suggests Perceptive Advisors underwrote the facility based on conservative revenue assumptions relative to management’s public guidance, consistent with institutional lender risk management practices.
Stay Ahead with the Latest Healthcare Insights
Join over 20,000 investors receiving FREE Big News Blasts from StockWire X, delivering breaking healthcare news and in-depth analysis on ASX biotech and healthcare stocks like AVITA Medical. These timely alerts provide comprehensive coverage and expert interpretation to help subscribers make informed decisions. To access these insights, simply click the “Free Alerts” button at the top of the page and subscribe to Big News Blasts today.